Clinical research
The drug was being evaluated in 237 adults with locally advanced or metastatic non-small cell lung cancer whose disease progressed while on or after previous platinum-based chemotherapy and checkpoint inhibitor immunotherapy.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
Microbiome company Seres Therapeutics announced the discontinuation of its Phase Ib trial of SER-401, an orally delivered consortia of bacteria that was intended to boost the efficacy of checkpoint inhibitors in patients with metastatic melanoma.
AnaptysBio started the week with some disappointing news for its lead antibody drug imsidolimab.
The findings from the late-stage trial of Vyrologix have not been published, but CytoDyn said it is preparing a manuscript of the study data for submission.
Merck and Ridgeback Biotherapeutics announced preliminary results from Ridgeback’s Phase IIa trial of molnupiravir in COVID-19.
It was another busy week for clinical trial announcements. Here’s a look.
Apellis Pharmaceuticals terminated its investigational COVID-19 asset after study data showed the therapeutic failed to reduce mortality rate in patients compared to standard of care.
Lilly’s tirzepatide has been proposed as a potentially effective treatment option that may rival the efficacy of semaglutide.
Gastrointestinal and autoimmune company Arena Pharmaceuticals announced mixed topline results for the Phase IIb trial of its oral cannabinoid receptor type 2 (CB2) agonist olorinab.
PRESS RELEASES